☆ 4.7 Letter

Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy

BLOOD (2022)

Get Full Text
Add to Collection

Journal

BLOOD
Volume 140, Issue 3, Pages 285-289

Publisher

AMER SOC HEMATOLOGY
DOI: 10.1182/blood.2022015832

Keywords

-

Categories

Hematology

Funding

  1. National Cancer Institute (NCI) Cancer Clinical Investigator Team Leadership Award
  2. NCI, National Institutes of Health [P30 CA016359]
  3. ASTEX Pharmaceuticals, Inc.

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.